Rivernorth Capital Management’s NRX Pharmaceuticals NRXP Stock Holding History

Rivernorth Capital Management’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-6,770	Closed	-$2.01M	–	282
2020 Q1	$2.01M	Sell	6,770 -17,230	-72%	-$1.85M	0.13%	151
2019 Q4	$2.54M	Hold	24,000	–	–	0.15%	117
2019 Q3	$2.54K	Hold	24,000	–	–	0.01%	136
2019 Q2	$2.53K	Hold	24,000	–	–	0.11%	115
2019 Q1	$2.48M	Hold	24,000	–	–	0.16%	110
2018 Q4	$2.45M	Hold	24,000	–	–	0.15%	137
2018 Q3	$2.4M	Buy	24,000 +5,992	+33%	+$596K	0.2%	89
2018 Q2	$1.78M	Buy	+18,008	New	+$1.78M	0.14%	107

Other funds holding NRXP

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

BCM

Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Rivernorth Capital Management's NRXP Position: Q2 2020 in Review

Rivernorth Capital Management sold out of NRX Pharmaceuticals (NRXP) in Q2 2020, closing a stake of 6,770 shares — an estimated $2.01M sold.

Rivernorth Capital Management first reported a position in NRXP in Q2 2018 and held it in 8 quarters. The position peaked at $2.54M in Q4 2019. 6 funds tracked by Wall St. Rank hold NRXP as of Q2 2020.

Rivernorth Capital Management reported no remaining NRX Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Rivernorth Capital Management sold 6,770 NRX Pharmaceuticals shares in Q2 2020, an estimated $2.01M.
Rivernorth Capital Management first reported a position in NRX Pharmaceuticals in Q2 2018 and held it in 8 quarters.
Rivernorth Capital Management's NRX Pharmaceuticals position peaked at $2.54M in Q4 2019.
6 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2020.

Based on Rivernorth Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.